| 1 |
Sernicola A, Ciolfi C, Miceli P, Alaibac M. Cutaneous Lymphoma and Antibody-Directed Therapies. Antibodies 2023;12:21. [DOI: 10.3390/antib12010021] [Reference Citation Analysis]
|
| 2 |
Vitiello P, Sagnelli C, Ronchi A, Franco R, Caccavale S, Mottola M, Pastore F, Argenziano G, Creta M, Calogero A, Fiorelli A, Casale B, Sica A. Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides. Healthcare (Basel) 2023;11. [PMID: 36833148 DOI: 10.3390/healthcare11040614] [Reference Citation Analysis]
|
| 3 |
Khodadoust MS, Mou E, Kim YH. Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome. Blood 2023;141:695-703. [PMID: 36379025 DOI: 10.1182/blood.2020008241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98:193-209. [PMID: 36226409 DOI: 10.1002/ajh.26760] [Reference Citation Analysis]
|
| 5 |
Martini DJ, Goyal S, Switchenko JM, Lechowicz MJ, Allen PB. African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center. Leuk Lymphoma 2022;63:2094-101. [PMID: 35481397 DOI: 10.1080/10428194.2022.2067999] [Reference Citation Analysis]
|
| 6 |
Parsons MW, Wada DA, Halwani AS, Tao R, Gaffney DK. Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2081322] [Reference Citation Analysis]
|
| 7 |
Lenskaya V, de Moll EH, Hussein S, Phelps RG. Subtlety of Granulomatous Mycosis Fungoides: A Retrospective Case Series Study and Proposal of Helpful Multimodal Diagnostic Approach With Literature Review. Am J Dermatopathol 2022. [PMID: 35476045 DOI: 10.1097/DAD.0000000000002181] [Reference Citation Analysis]
|
| 8 |
Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:1313-28. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Grandi V, Baldo A, Berti E, Quaglino P, Rupoli S, Alaibac M, Alberti-Violetti S, Amerio P, Brazzelli V, Bruni PL, Calzavara-Pinton P, Parodi A, Cozzani E, Burlando M, Fargnoli MC, Gambini D, Iacovelli P, Pacifico A, Longo C, Monfrecola G, Motolese A, Mozzicafreddo G, Cota C, Pigatto P, Pileri A, Savoia P, Simonacci M, Venturini M, Offidani A, Molinelli E, Pellegrino M, Trovato E, Piccinno R, Lawrence K, Pimpinelli N. Italian expert-based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an e-Delphi consensus. Photodermatol Photoimmunol Photomed 2021;37:334-42. [PMID: 33458864 DOI: 10.1111/phpp.12658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Zhang P, Zhang M. Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma. Front Oncol 2021;11:663961. [PMID: 34249700 DOI: 10.3389/fonc.2021.663961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Reneau JC, Wilcox RA. Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. Semin Hematol 2021;58:103-13. [PMID: 33906720 DOI: 10.1053/j.seminhematol.2021.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Mascolo M, Travaglino A, Varricchio S, Russo D, Sabattini E, Agostinelli C, Bertuzzi C, Baldo A, Pileri A, Picardi M, Pane F, Staibano S. Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Arch 2021;478:961-8. [PMID: 33098490 DOI: 10.1007/s00428-020-02952-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
|
| 14 |
Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM. Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers (Basel) 2020;12:E2311. [PMID: 32824427 DOI: 10.3390/cancers12082311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 15 |
Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am 2019;33:103-20. [PMID: 30497668 DOI: 10.1016/j.hoc.2018.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 16 |
Dalal M, Mitchell S, Mccloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Review of Hematology 2020;13:405-19. [DOI: 10.1080/17474086.2020.1717945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Campbell BA, Ryan G, McCormack C, Tangas E, Bressel M, Twigger R, Buelens O, van der Weyden C, Prince HM. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. Cancers (Basel) 2019;11:E1758. [PMID: 31717353 DOI: 10.3390/cancers11111758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 18 |
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 539] [Cited by in F6Publishing: 565] [Article Influence: 134.8] [Reference Citation Analysis]
|
| 19 |
Wilcox RA. ECP in the spotLIGHT. Blood 2019;134:1275-7. [DOI: 10.1182/blood.2019002790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 20 |
Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 21 |
Gao C, Mccormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 2019;134:1346-50. [DOI: 10.1182/blood.2019000765] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 22 |
Fujii K, Kanekura T. Next-Generation Sequencing Technologies for Early-Stage Cutaneous T-Cell Lymphoma. Front Med (Lausanne) 2019;6:181. [PMID: 31457014 DOI: 10.3389/fmed.2019.00181] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Murga-Zamalloa C, Wilcox RA. GATA-3 in T-cell lymphoproliferative disorders. IUBMB Life 2020;72:170-7. [PMID: 31317631 DOI: 10.1002/iub.2130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 24 |
Nicolay JP, Assaf C. Therapie der Mycosis fungoides und des Sézary-Syndroms. Hautarzt 2017;68:702-10. [DOI: 10.1007/s00105-017-4021-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 25 |
Takahashi S, Wada H, Hakuta A, Watanabe T, Kanbara T, Mukai Y, Koike I, Aihara M. Successful treatment of mycosis fungoides (tumor stage) with low-dose oral etoposide in combination with local electron beam radiation therapy : Report of two cases. Skin Cancer 2019;33:179-184. [DOI: 10.5227/skincancer.33.179] [Reference Citation Analysis]
|
| 26 |
Lopez AT, Bates S, Geskin L. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. Am J Clin Dermatol 2018;19:805-19. [PMID: 30173294 DOI: 10.1007/s40257-018-0380-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 27 |
Kinoshita-Ise M, Ouchi T, Izumi E, Kawaguchi O, Nagao K, Amagai M, Funakoshi T. Combination of low-dose total skin electron beam therapy and subsequent localized skin electron beam therapy as a therapeutic option for advanced-stage mycosis fungoides. Clin Exp Dermatol 2018;43:437-40. [PMID: 29266332 DOI: 10.1111/ced.13347] [Reference Citation Analysis]
|
| 28 |
Boonstra PS, Polk A, Brown N, Hristov AC, Bailey NG, Kaminski MS, Phillips T, Devata S, Mayer T, Wilcox RA. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas. Am J Hematol 2017;92:1287-94. [PMID: 28842936 DOI: 10.1002/ajh.24895] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 29 |
Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 31 |
von Dücker L, Dippel E, Nashan D. Management primär kutaner Lymphome. hautnah dermatologie 2017;33:44-49. [DOI: 10.1007/s15012-017-2306-0] [Reference Citation Analysis]
|
| 32 |
Tsutsui K, Koga M, Imafuku S. Improvement of ulcerative lesion of mycosis fungoides by bexarotene. Skin Cancer 2017;32:192-196. [DOI: 10.5227/skincancer.32.192] [Reference Citation Analysis]
|
